Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well giving rituximab together with combination
chemotherapy and bortezomib works in treating patients with untreated mantle cell lymphoma.
Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some
block the ability of cancer cells to grow and spread. Others find cancer cells and help kill
them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as
cyclophosphamide, doxorubicin, vincristine, and dexamethasone, work in different ways to stop
the growth of cancer cells, either by killing the cells or stopping them from dividing.
Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for
cell growth. Giving rituximab together with combination chemotherapy and bortezomib may kill
more cancer cells.
Treatment consists of six agents: bortezomib (Vc), rituximab (R), cyclophosphamide (C),
vincristine (V), doxorubicin (A), and dexamethasone (D) (VcR-CVAD).